TIAA CREF Investment Management LLC lowered its position in shares of Amedisys Inc (NASDAQ:AMED) by 16.4% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 135,240 shares of the health services provider’s stock after selling 26,518 shares during the period. TIAA CREF Investment Management LLC’s holdings in Amedisys were worth $6,909,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Great West Life Assurance Co. Can increased its position in Amedisys by 8.0% in the first quarter. Great West Life Assurance Co. Can now owns 40,062 shares of the health services provider’s stock worth $2,045,000 after buying an additional 2,960 shares in the last quarter. Monarch Partners Asset Management LLC bought a new stake in Amedisys during the first quarter valued at $8,984,000. First Midwest Bank Trust Division raised its stake in Amedisys by 3.0% in the first quarter. First Midwest Bank Trust Division now owns 34,740 shares of the health services provider’s stock valued at $1,775,000 after buying an additional 1,012 shares during the last quarter. Russell Investments Group Ltd. raised its stake in Amedisys by 77.7% in the first quarter. Russell Investments Group Ltd. now owns 36,295 shares of the health services provider’s stock valued at $1,854,000 after buying an additional 15,875 shares during the last quarter. Finally, State of Alaska Department of Revenue raised its stake in Amedisys by 2.3% in the first quarter. State of Alaska Department of Revenue now owns 3,080 shares of the health services provider’s stock valued at $157,000 after buying an additional 70 shares during the last quarter. Hedge funds and other institutional investors own 99.80% of the company’s stock.
Shares of Amedisys Inc (NASDAQ AMED) traded up 0.94% during trading on Tuesday, hitting $49.50. The stock had a trading volume of 482,398 shares. The stock has a market cap of $1.68 billion, a price-to-earnings ratio of 42.31 and a beta of 0.89. Amedisys Inc has a 12 month low of $34.58 and a 12 month high of $65.91. The company’s 50 day moving average price is $58.14 and its 200 day moving average price is $54.09.
Amedisys (NASDAQ:AMED) last posted its quarterly earnings data on Wednesday, July 26th. The health services provider reported $0.62 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.50 by $0.12. The firm had revenue of $378.80 million for the quarter, compared to the consensus estimate of $380.80 million. Amedisys had a return on equity of 13.71% and a net margin of 2.70%. The company’s quarterly revenue was up 5.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.42 EPS. Equities research analysts expect that Amedisys Inc will post $2.21 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: “TIAA CREF Investment Management LLC Sells 26,518 Shares of Amedisys Inc (AMED)” was published by BBNS and is the sole property of of BBNS. If you are viewing this report on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The legal version of this report can be accessed at https://baseballnewssource.com/markets/amedisys-inc-amed-shares-sold-by-tiaa-cref-investment-management-llc-updated-updated-updated/1196756.html.
AMED has been the topic of several recent research reports. Jefferies Group LLC restated a “buy” rating and set a $57.00 price target on shares of Amedisys in a report on Friday, April 28th. Mizuho upgraded Amedisys from a “neutral” rating to a “buy” rating and set a $65.00 price target on the stock in a report on Wednesday, May 3rd. Zacks Investment Research lowered Amedisys from a “buy” rating to a “hold” rating in a report on Tuesday, May 2nd. BidaskClub lowered Amedisys from a “hold” rating to a “sell” rating in a report on Saturday. Finally, Royal Bank Of Canada restated a “hold” rating and set a $56.00 price target on shares of Amedisys in a report on Monday, June 5th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and four have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $56.50.
In related news, insider Lawrence R. Pernosky sold 11,500 shares of the business’s stock in a transaction on Wednesday, May 10th. The stock was sold at an average price of $58.97, for a total value of $678,155.00. Following the sale, the insider now owns 30,093 shares in the company, valued at approximately $1,774,584.21. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Bruce D. Perkins acquired 500 shares of the business’s stock in a transaction that occurred on Thursday, May 25th. The stock was purchased at an average price of $59.69 per share, for a total transaction of $29,845.00. Following the acquisition, the director now directly owns 13,331 shares in the company, valued at approximately $795,727.39. The disclosure for this purchase can be found here. 2.80% of the stock is currently owned by insiders.
Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.
Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with our FREE daily email newsletter.